3D Medicines (Sichuan) Co., Ltd.
Registry sponsor category
Industry
- Other names
- 3D Medicines (Sichuan) Co., Ltd.
- Company name
- 3D Medicines (Sichuan) Co., Ltd.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (11)
- A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
- ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
- KN035 for dMMR/MSI-H Advanced Solid Tumors
- Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
- Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors
- Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
- Phase I Trial of Envafolimab for Healthy Male Subjects
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
- Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
- Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer